Recent developments include the closing of a $35 million public offering in January 2026, issuance of a prepayment notice for convertible debenture financing, and termination of a standby equity purchase agreement. The company has strengthened liquidity and eliminated secured debt. Market conditions noted in recent news reflect broader economic factors rather than company-specific events.

• Streamex Corp. announced the closing of a $35 million public offering in January 2026, strengthening liquidity [N5].
• The company issued a prepayment notice for previously announced convertible debenture financing and terminated a standby equity purchase agreement in January 2026 [N6].
• Streamex announced pricing of the $35 million public offering in January 2026 [N7].
• The company announced the proposed public offering in January 2026 [N8].
• Recent market news highlights include lower stock market settlements due to rising bond yields and significant declines in the Japanese market, reflecting broader economic conditions [N1][N2].
• Other recent news covers market volatility in China and commodity markets, not directly related to Streamex [N3][N4].

Streamex's acquisition of Streamex Exchange and subsequent launch of the GLDY token position the company to capitalize on the growing interest in tokenized real-world assets. The institutional-grade platform and infrastructure could attract issuers and investors seeking compliant digital asset solutions backed by tangible commodities. The company's strong liquidity position following recent public offerings and debt repayments supports ongoing development and commercialization efforts. Strategic partnerships and regulatory progress could enhance adoption and revenue generation from fee-based services on the platform.

The company faces significant challenges including minimal current revenue, high net losses driven by non-cash charges, and reliance on future regulatory approvals and market adoption for its tokenization platform. The legacy medical device business has limited commercial activity and operations of majority-owned subsidiaries are dormant or on hold. The company may require additional financing, which could dilute shareholders or impose restrictive terms. Market volatility, competition, and execution risks could delay or limit the platform's commercial success and revenue generation.

Streamex's moat lies in its institutional-grade blockchain platform for tokenization of real-world assets, a niche with high barriers to entry due to regulatory complexity, technology development, and the need for compliance infrastructure. The company's early mover advantage in commodity-backed digital tokens, starting with gold, and its integration of backend infrastructure provide a foundation for potential network effects and partnerships. However, the platform is in early commercialization stages with limited revenue, and the company faces competition from other digital asset infrastructure providers. The legacy medical device business offers some diversification but is currently limited in commercial scale.

• Regulatory and Market Adoption Risks: The success of Streamex's tokenization platform depends on regulatory developments and market acceptance of digital tokens backed by real-world assets. Changes in regulations or slow adoption could impact revenue potential.
• Financial and Liquidity Risks: The company has incurred significant net losses and negative cash flows. While recent financing improved liquidity, future capital needs may arise, and financing on acceptable terms is not guaranteed.
• Execution and Commercialization Risks: Streamex's platform is in early stages with limited revenue. Execution risks include technology development, platform maturity, and ability to monetize offerings through fee-based services.
• Legacy Business and Subsidiary Risks: The legacy medical device business has limited recent commercial activity, and majority-owned subsidiaries ViralClear and BioSig AI are dormant or on hold, which may affect overall business stability.

• Streamex Corp. completed acquisition of Streamex Exchange Corporation on May 28, 2025, expanding from medical device technology to a diversified technology platform focused on tokenized finance and digitization of real-world assets (RWAs) [S1].
• The company operates an institutional-grade blockchain-based platform enabling issuance, trading, and backend infrastructure for digital tokens backed by tangible commodities, starting with gold [S1].
• Streamex continues to operate its legacy medical device business focused on the PURE EP™ Platform for cardiac electrophysiology, though this business has limited recent commercial activity [S1].
• Streamex Exchange platform was in development stage as of December 31, 2025, with no revenue generated by that date; launched GLDY token and began accepting subscriptions in 2026 [S1].
• Revenue has been minimal historically, with $0 revenue in 2025 and $40,000 in 2024, primarily from PURE EP™ related services [S1].
• Net loss attributable to common stockholders was $462.8 million for the year ended December 31, 2025, compared to $10.5 million in 2024, driven by non-cash losses related to derivative liabilities and increased stock-based compensation [S1].
• Research and development expenses decreased significantly in 2025 to $31,000 from $832,000 in 2024, reflecting a shift in focus and resource allocation [S1].
• General and administrative expenses increased to $67.5 million in 2025 from $11.6 million in 2024, largely due to $57.1 million in non-cash stock-based compensation related to equity awards and acquisition-related costs [S1].
• As of March 31, 2026, Streamex had cash and cash equivalents of $6.86 million, current assets of $45.9 million, current liabilities of $3.3 million, resulting in a strong current ratio of 13.9 and cash ratio of 2.08 [S2].
• The company completed a $35 million public offering in January 2026 and repaid outstanding secured convertible debentures, eliminating secured debt and strengthening liquidity [N5][S1].
• Streamex operates as a single reportable segment, with consolidated financial performance reviewed by the Chief Operating Decision Maker [S1].
• The company holds majority interests in subsidiaries ViralClear Pharmaceuticals (dormant) and BioSig AI Sciences (operations on hold) [S1].
• Streamex's capital strategy includes maintaining liquidity to support operations, product development, and strategic initiatives, with potential future capital raises through equity, partnerships, grants, or debt [S1].
• The company faces risks related to regulatory developments, market adoption of tokenized products, competition, and the ability to monetize its platform [S1].
• Recent news includes the closing of a $35 million public offering in January 2026 and issuance of a prepayment notice for convertible debenture financing [N5][N6][N7][N8].
• Market conditions and broader economic factors such as rising bond yields and international market volatility have been noted in recent news but are not company-specific [N1][N2][N3][N4].